The latest results [ 65 ] showed that the PFS hazard ratios of the niraparib group in the overall cohort, homologous recombination deficiency (HRD) and homologous recombination proficient (HRP) subgroups were 0.66, 0.51, and 0.67, respectively, indicating that niraparib can significantly prolong PFS of patients, but in terms of OS, the hazard ratios of each population were close to 1, which did not reach statistical significance.
← all excerpts
Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies.
1
—
—